Identifying mechanisms of harm and susceptibility in individual tobacco users can greatly assist in reducing disease from tobacco. To do harm, the carcinogens in tobacco smoke must be absorbed and activated by the body. Biomarkers in blood for specific tobacco carcinogens have been identified that measure the effective dose; other biomarkers measure the degree to which those carcinogens have become capable of damaging DNA and so indicate the individual phenotypic susceptibility. This proposed study would estimate the association of biomarkers of tobacco carcinogen exposure and metabolic activation in smokers to their risk of developing lung cancer. The study would be nested in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO), a randomized trial of multi-site cancer screening in over 150,000 men and women nationwide, about 7,000 of whom are current smokers. The PLCO is an ideal epidemiologic setting for this activity, because it provides a well characterized smoking population with rigorously collected data, has an associated, extensive biorepository of blood samples collected at screening visits, and eliminates a major source of bias found in partially screened populations. From a source cohort of PLCO bio-repository participants who reported smoking on their baseline questionnaire, a sample of 300 incident lung cancer cases and 300 controls will be drawn and their demographic and baseline data obtained. After pooling their blood samples into triplets of similar risk (yielding 100 case and 100 control samples), each pooled sample will be analyzed to measure the specified metabolites. The biomarker levels in lung cancer subjects will be compared to those in non-lung cancer subjects and regression estimates will be made of the odds ratios of developing lung cancer associated with these biomarkers. In order to evaluate the variability of biomarker levels in individual smokers over time, a separate, longitudinal study will recruit 25 men and 25 women who are current smokers to give blood samples every two months for a year. These data will be used to strengthen the results of the case-control study by allowing a sensitivity analysis based on the within subject variance and to provide improved estimates. If successful, these data will improve 1) understanding of lung cancer etiology and 2) predictive models for lung cancer. We project that carcinogen metabolite phenotyping will enhance prevention, early detection, and risk reduction. Moreover, this study will validate the relationship to disease of biomarkers, thus supporting their use in other projects of this TTURC.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Specialized Center (P50)
Project #
2P50DA013333-06
Application #
6863429
Study Section
Special Emphasis Panel (ZCA1-GRB-I (O1))
Project Start
2004-09-01
Project End
2009-05-31
Budget Start
2004-09-01
Budget End
2005-05-31
Support Year
6
Fiscal Year
2004
Total Cost
$93,117
Indirect Cost
Name
University of Minnesota Twin Cities
Department
Type
DUNS #
555917996
City
Minneapolis
State
MN
Country
United States
Zip Code
55455
Burns, Rachel J; Rothman, Alexander J; Fu, Steven S et al. (2016) Longitudinal Care Improves Cessation in Smokers Who Do Not Initially Respond to Treatment by Increasing Cessation Self-Efficacy, Satisfaction, and Readiness to Quit: A Mediated Moderation Analysis. Ann Behav Med 50:58-69
Konorev, Dmitri; Koopmeiners, Joseph S; Tang, Yijin et al. (2015) Measurement of the Heterocyclic Amines 2-Amino-9H-pyrido[2,3-b]indole and 2-Amino-1-methyl-6-phenylimidazo[4,5-b]pyridine in Urine: Effects of Cigarette Smoking. Chem Res Toxicol 28:2390-9
Hatsukami, Dorothy K; Donny, Eric C; Koopmeiners, Joseph S et al. (2015) Compensatory smoking from gradual and immediate reduction in cigarette nicotine content. Cancer Epidemiol Biomarkers Prev 24:472-6
Burns, Rachel J; Rothman, Alexander J; Fu, Steven S et al. (2014) The relation between social support and smoking cessation: revisiting an established measure to improve prediction. Ann Behav Med 47:369-75
Oliver, Andrew J; Jensen, Joni A; Vogel, Rachel I et al. (2013) Flavored and nonflavored smokeless tobacco products: rate, pattern of use, and effects. Nicotine Tob Res 15:88-92
Knezevich, Aleksandar; Muzic, John; Hatsukami, Dorothy K et al. (2013) Nornicotine nitrosation in saliva and its relation to endogenous synthesis of N'-nitrosonornicotine in humans. Nicotine Tob Res 15:591-5
Anderson, Kristin E; Mongin, Steven J; Sinha, Rashmi et al. (2012) Pancreatic cancer risk: associations with meat-derived carcinogen intake in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO) cohort. Mol Carcinog 51:128-37
Stepanov, Irina; Knezevich, Aleksandar; Zhang, Liqin et al. (2012) Carcinogenic tobacco-specific N-nitrosamines in US cigarettes: three decades of remarkable neglect by the tobacco industry. Tob Control 21:44-8
Hecht, Stephen S; Stepanov, Irina; Hatsukami, Dorothy K (2011) Major tobacco companies have technology to reduce carcinogen levels but do not apply it to popular smokeless tobacco products. Tob Control 20:443
Harris, Andrew C; Pentel, Paul R; Burroughs, Danielle et al. (2011) A lack of association between severity of nicotine withdrawal and individual differences in compensatory nicotine self-administration in rats. Psychopharmacology (Berl) 217:153-66

Showing the most recent 10 out of 132 publications